NDAORALSOLUTION
Approved
Jun 2011
Lifecycle
Peak
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 43m ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
REZIRA is a fixed-dose oral solution combining hydrocodone bitartrate (opioid analgesic) and pseudoephedrine hydrochloride (decongestant) approved in 2011. It is indicated for cough and congestion relief associated with upper respiratory conditions. The combination leverages opioid antitussive activity with sympathomimetic nasal decongestant action.
Peak
Product is at peak maturity with established market presence; teams are focused on maintaining market position rather than growth expansion.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
REZIRA offers limited career growth due to zero linked job postings and peak lifecycle stage; career advancement is constrained by the product's mature status and absence of major launches or expansions. Roles are primarily commercial execution-focused with minimal opportunities for clinical or research development.
Brand ManagerField Sales Representative
Worked on REZIRA at Design Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.